Prediction of hospital-onset COVID-19 infections using dynamic networks of patient contact: an international retrospective cohort study.


Journal

The Lancet. Digital health
ISSN: 2589-7500
Titre abrégé: Lancet Digit Health
Pays: England
ID NLM: 101751302

Informations de publication

Date de publication:
08 2022
Historique:
received: 26 09 2021
revised: 19 03 2022
accepted: 25 04 2022
entrez: 22 7 2022
pubmed: 23 7 2022
medline: 27 7 2022
Statut: ppublish

Résumé

Real-time prediction is key to prevention and control of infections associated with health-care settings. Contacts enable spread of many infections, yet most risk prediction frameworks fail to account for their dynamics. We developed, tested, and internationally validated a real-time machine-learning framework, incorporating dynamic patient-contact networks to predict hospital-onset COVID-19 infections (HOCIs) at the individual level. We report an international retrospective cohort study of our framework, which extracted patient-contact networks from routine hospital data and combined network-derived variables with clinical and contextual information to predict individual infection risk. We trained and tested the framework on HOCIs using the data from 51 157 hospital inpatients admitted to a UK National Health Service hospital group (Imperial College Healthcare NHS Trust) between April 1, 2020, and April 1, 2021, intersecting the first two COVID-19 surges. We validated the framework using data from a Swiss hospital group (Department of Rehabilitation, Geneva University Hospitals) during a COVID-19 surge (from March 1 to May 31, 2020; 40 057 inpatients) and from the same UK group after COVID-19 surges (from April 2 to Aug 13, 2021; 43 375 inpatients). All inpatients with a bed allocation during the study periods were included in the computation of network-derived and contextual variables. In predicting patient-level HOCI risk, only inpatients spending 3 or more days in hospital during the study period were examined for HOCI acquisition risk. The framework was highly predictive across test data with all variable types (area under the curve [AUC]-receiver operating characteristic curve [ROC] 0·89 [95% CI 0·88-0·90]) and similarly predictive using only contact-network variables (0·88 [0·86-0·90]). Prediction was reduced when using only hospital contextual (AUC-ROC 0·82 [95% CI 0·80-0·84]) or patient clinical (0·64 [0·62-0·66]) variables. A model with only three variables (ie, network closeness, direct contacts with infectious patients [network derived], and hospital COVID-19 prevalence [hospital contextual]) achieved AUC-ROC 0·85 (95% CI 0·82-0·88). Incorporating contact-network variables improved performance across both validation datasets (AUC-ROC in the Geneva dataset increased from 0·84 [95% CI 0·82-0·86] to 0·88 [0·86-0·90]; AUC-ROC in the UK post-surge dataset increased from 0·49 [0·46-0·52] to 0·68 [0·64-0·70]). Dynamic contact networks are robust predictors of individual patient risk of HOCIs. Their integration in clinical care could enhance individualised infection prevention and early diagnosis of COVID-19 and other nosocomial infections. Medical Research Foundation, WHO, Engineering and Physical Sciences Research Council, National Institute for Health Research (NIHR), Swiss National Science Foundation, and German Research Foundation.

Sections du résumé

BACKGROUND
Real-time prediction is key to prevention and control of infections associated with health-care settings. Contacts enable spread of many infections, yet most risk prediction frameworks fail to account for their dynamics. We developed, tested, and internationally validated a real-time machine-learning framework, incorporating dynamic patient-contact networks to predict hospital-onset COVID-19 infections (HOCIs) at the individual level.
METHODS
We report an international retrospective cohort study of our framework, which extracted patient-contact networks from routine hospital data and combined network-derived variables with clinical and contextual information to predict individual infection risk. We trained and tested the framework on HOCIs using the data from 51 157 hospital inpatients admitted to a UK National Health Service hospital group (Imperial College Healthcare NHS Trust) between April 1, 2020, and April 1, 2021, intersecting the first two COVID-19 surges. We validated the framework using data from a Swiss hospital group (Department of Rehabilitation, Geneva University Hospitals) during a COVID-19 surge (from March 1 to May 31, 2020; 40 057 inpatients) and from the same UK group after COVID-19 surges (from April 2 to Aug 13, 2021; 43 375 inpatients). All inpatients with a bed allocation during the study periods were included in the computation of network-derived and contextual variables. In predicting patient-level HOCI risk, only inpatients spending 3 or more days in hospital during the study period were examined for HOCI acquisition risk.
FINDINGS
The framework was highly predictive across test data with all variable types (area under the curve [AUC]-receiver operating characteristic curve [ROC] 0·89 [95% CI 0·88-0·90]) and similarly predictive using only contact-network variables (0·88 [0·86-0·90]). Prediction was reduced when using only hospital contextual (AUC-ROC 0·82 [95% CI 0·80-0·84]) or patient clinical (0·64 [0·62-0·66]) variables. A model with only three variables (ie, network closeness, direct contacts with infectious patients [network derived], and hospital COVID-19 prevalence [hospital contextual]) achieved AUC-ROC 0·85 (95% CI 0·82-0·88). Incorporating contact-network variables improved performance across both validation datasets (AUC-ROC in the Geneva dataset increased from 0·84 [95% CI 0·82-0·86] to 0·88 [0·86-0·90]; AUC-ROC in the UK post-surge dataset increased from 0·49 [0·46-0·52] to 0·68 [0·64-0·70]).
INTERPRETATION
Dynamic contact networks are robust predictors of individual patient risk of HOCIs. Their integration in clinical care could enhance individualised infection prevention and early diagnosis of COVID-19 and other nosocomial infections.
FUNDING
Medical Research Foundation, WHO, Engineering and Physical Sciences Research Council, National Institute for Health Research (NIHR), Swiss National Science Foundation, and German Research Foundation.

Identifiants

pubmed: 35868812
pii: S2589-7500(22)00093-0
doi: 10.1016/S2589-7500(22)00093-0
pmc: PMC9296105
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e573-e583

Subventions

Organisme : MRF
ID : MRF_MRF-145-0004-TPG-AVISO
Pays : United Kingdom

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests After the analysis in this paper was completed, AM and MB received funding from UKRI Research England via the MedTech SuperConnector (awarded on June 1, 2022) for commercial viability testing of infection prevention models. All other authors declare no competing interests.

Références

Clin Infect Dis. 2022 Mar 23;74(6):1097-1100
pubmed: 34145449
Science. 2020 May 8;368(6491):
pubmed: 32234805
Science. 2021 Apr 9;372(6538):
pubmed: 33658326
J Hosp Infect. 2020 Dec;106(4):678-697
pubmed: 32956786
Elife. 2021 Aug 24;10:
pubmed: 34425938
Science. 2021 Jul 9;373(6551):162-163
pubmed: 34244400
Phys Rev Lett. 2001 Apr 2;86(14):3200-3
pubmed: 11290142
Ann Intern Med. 2020 May 05;172(9):577-582
pubmed: 32150748
BMJ Qual Saf. 2021 Jun;30(6):457-466
pubmed: 33495288
J Med Internet Res. 2020 May 26;22(5):e19437
pubmed: 32412416
Am J Infect Control. 2010 Apr;38(3):173-81
pubmed: 20022405
J Am Med Dir Assoc. 2020 Nov;21(11):1574-1576.e2
pubmed: 32994117
Int J Environ Res Public Health. 2021 Jan 09;18(2):
pubmed: 33435324
JAMA Intern Med. 2021 Oct 1;181(10):1343-1350
pubmed: 34424260
Infect Control Hosp Epidemiol. 2011 Mar;32(3):201-6
pubmed: 21460503
EClinicalMedicine. 2020 Dec;29:100630
pubmed: 33200120
Phys Rev E Stat Nonlin Soft Matter Phys. 2002 Jul;66(1 Pt 2):016128
pubmed: 12241447
Antimicrob Resist Infect Control. 2021 Jan 6;10(1):7
pubmed: 33407833
J Infect. 2021 Oct;83(4):473-482
pubmed: 34332019
J Infect Dis. 1978 Dec;138(6):811-9
pubmed: 105056
J Infect Public Health. 2020 May;13(5):667-673
pubmed: 32340833
Patterns (N Y). 2021 Apr 02;2(4):100227
pubmed: 33982022
Lancet. 2020 Mar 14;395(10227):846-848
pubmed: 32151325
Lancet Digit Health. 2021 Jun;3(6):e349-e359
pubmed: 34045001
Nature. 2005 Nov 17;438(7066):355-9
pubmed: 16292310
Clin Infect Dis. 2020 Jul 28;71(15):786-792
pubmed: 32211755
J Hosp Infect. 2021 Sep;115:44-50
pubmed: 34098049
J Hosp Infect. 2021 Nov;117:124-134
pubmed: 34461177
Lancet Digit Health. 2020 Dec;2(12):e658-e666
pubmed: 33078140
Lancet Digit Health. 2021 Feb;3(2):e78-e87
pubmed: 33509388
J Hosp Infect. 2020 Nov;106(3):562-569
pubmed: 32745591
Emerg Infect Dis. 2020 Jul;26(7):1628-1631
pubmed: 32240078

Auteurs

Ashleigh Myall (A)

Department of Infectious Disease, Imperial College London, London, UK; Department of Mathematics, Imperial College London, London, UK; National Institute for Health Research Health Protection Research Unit in HCAI and AMR, Imperial College London, London, UK. Electronic address: a.myall19@imperial.ac.uk.

James R Price (JR)

National Institute for Health Research Health Protection Research Unit in HCAI and AMR, Imperial College London, London, UK; Imperial College Healthcare NHS Trust, Imperial College London, London, UK.

Robert L Peach (RL)

Department of Mathematics, Imperial College London, London, UK; Department of Brain Sciences, Imperial College London, London, UK; Department of Neurology, University Hospital of Würzburg, Würzburg, Germany.

Mohamed Abbas (M)

MRC Centre for Global Infectious Disease Analysis, Imperial College London, London, UK; Infection Control Programme, Geneva University Hospitals, Geneva, Switzerland.

Sid Mookerjee (S)

National Institute for Health Research Health Protection Research Unit in HCAI and AMR, Imperial College London, London, UK; Imperial College Healthcare NHS Trust, Imperial College London, London, UK.

Nina Zhu (N)

Department of Infectious Disease, Imperial College London, London, UK; National Institute for Health Research Health Protection Research Unit in HCAI and AMR, Imperial College London, London, UK.

Isa Ahmad (I)

Department of Infectious Disease, Imperial College London, London, UK; National Institute for Health Research Health Protection Research Unit in HCAI and AMR, Imperial College London, London, UK.

Damien Ming (D)

Department of Infectious Disease, Imperial College London, London, UK; National Institute for Health Research Health Protection Research Unit in HCAI and AMR, Imperial College London, London, UK.

Farzan Ramzan (F)

Department of Infectious Disease, Imperial College London, London, UK; National Institute for Health Research Health Protection Research Unit in HCAI and AMR, Imperial College London, London, UK.

Daniel Teixeira (D)

Infection Control Programme, Geneva University Hospitals, Geneva, Switzerland.

Christophe Graf (C)

Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, Switzerland.

Andrea Y Weiße (AY)

School of Biological Sciences and School of Informatics, University of Edinburgh, Edinburgh, UK.

Stephan Harbarth (S)

Infection Control Programme, Geneva University Hospitals, Geneva, Switzerland.

Alison Holmes (A)

Department of Infectious Disease, Imperial College London, London, UK; National Institute for Health Research Health Protection Research Unit in HCAI and AMR, Imperial College London, London, UK.

Mauricio Barahona (M)

Department of Mathematics, Imperial College London, London, UK. Electronic address: m.barahona@imperial.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH